Phase 2 Grant definition

Phase 2 Grant means £VALUE being the maximum amount of grant payable to the Grant Recipient by the Council during Phase 2 of the Refurbishment Programme in accordance with the provisions of Schedule 1
Sample 1Sample 2Sample 3
Phase 2 Grant means a Grant for which a Participating Kabupaten is eligible to apply in respect of Sub-projects: (i) upon its satisfying the eligibility criteria set forth in: (x) the Local Governance Reform Framework for the provision of said grants to Participating Kabupatens in the twelve (12) month period following that covered by Phase 1 Grants; and (y) Part 2 of Annex B to Schedule 4 of this Agreement; and (ii) in accordance with the relevant provisions concerning said Grants in the Project Operational Manual, which Sub-projects are to be financed in the Fiscal Year immediately following the attainment of such eligibility; and “Phase 2 Grants” means Phase 2 Grants collectively.
Sample 1Sample 2

Examples of Phase 2 Grant in a sentence

  • SME Instrument Phase 1 and SME Instrument Phase 2 each have their own specific Grant Agreements (see annotated specific SME Instrument Phase 1 Grant Agreement and annotated specific SME Instrument Phase 2 Grant Agreement).

  • Phase 2: Grant Review Subcommittee MeetingsThe second phase of the application review process is comprised of two Grant Review Subcommittee meetings.

  • The application requires completion and submission of all of the following materials unless the applicant elects to carry forward their prior HAPP Phase 2 Grant application.

  • HAPP Phase 2 Reopened is designed to allow more time for applicants to submit funding requests based on the HAPP Phase 2 award guidance in light of the recent COVID-19 surges facing Rhode Island hospitals.Previous applicants may elect to update and resubmit their HAPP Phase 2 Grant applications or carry forward their prior HAPP Phase 2 Grant application.

  • The following methodology is consistent with the HAPP Phase 2 Grant methodology.

  • The PR sought inputs from the SRs and SSRs before finalizing them and they were later oriented on their proper use during the orientation sessions on the Rd 8 Phase 2 Grant.

  • Main Variations & Management ActionOverviews by Theme of the key issues are as follows: A2.1 Pride in the Bay – Changes/Significant Revision of timing/budget Torre Abbey Mansion Phase 2 Grant monies from Heritage Lottery for design works were initially thought to be part of overall funding however it has been confirmed that this is, in fact, additional funding so the budget for the main works can increase by £0.130m to match additional resources.

  • In exceptional cases, defined in the Work Programme2, whenever the funding rate can be up to 100%, the General Model Grant Agreement applies for Phase 2 instead of the specific SME Instrument Phase 2 Grant Agreement.

  • My business’s application is still under review for a Phase 1 Grant; can I apply for the same business for Phase 2 funding?- If an applicant is currently under review in the Phase 1 Grant Program, the same business can also apply for the Phase 2 Grant.

  • See Appendix 3 sets out Welsh Governments accommodation standards for accommodation provided through Phase 2 Grant funding.

Related to Phase 2 Grant

  • Phase 2 means the second implementation phase of this section, beginning June 1, 2022 and continuing thereafter.

  • Phase 1 means the first implementation phase of this section, beginning June 1, 2018 and ending May 31, 2022.

  • Phase 2 Trial means a human clinical trial conducted on study subjects with the disease or condition being studied for the principal purpose of achieving a preliminary determination of efficacy or appropriate dosage ranges, as further described in 21 C.F.R. §312.21(b) (including any such clinical study in any country other than the United States).

  • Continuous Improvement Plan means a plan for improving the provision of the Goods and/or Services and/or reducing the Charges produced by the Supplier pursuant to Framework Schedule 12 (Continuous Improvement and Benchmarking);

  • Phase 2 Clinical Trial means a human clinical trial of a product in any country that would satisfy the requirements of 21 C.F.R. 312.21(b) and is intended to explore a variety of doses, dose response, and duration of effect, and to generate initial evidence of clinical safety and activity in a target patient population, or a similar clinical study prescribed by the relevant Regulatory Authorities in a country other than the United States.

  • Phase II Study means a human clinical trial, for which the primary endpoints include a determination of dose ranges and/or a preliminary determination of efficacy in patients being studied as described in 21 C.F.R. § 312.21(b) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  • Phase I Study means a study in humans which provides for the first introduction into humans of a product, conducted in healthy volunteers or patients to obtain information on product safety, tolerability, pharmacological activity or pharmacokinetics, as more fully defined in 21 C.F.R. § 312.21(a) (or the non-United States equivalent thereof).

  • Phase 3 means the period commencing on the day after the Phase 2 implementation date and ending on the Phase 3 implementation date (as defined below).

  • Area Plan or “multiyear area plan” means a document, developed in accordance with the uniform area plan format and IAPI issued by the department, that is submitted to the department every four years, with annual updates, by an AAA in order to receive subgrants from the department’s grants.

  • Phase 1 Trial means, with respect to a Licensed Product, a clinical trial (or — in case of a multi-phase clinical trial — those parts of a clinical trial) in line with the provisions of 21CFR312, Section 21 (a).

  • Phase 3 Trial means a human clinical trial of a Product on a sufficient number of subjects that is designed to establish that a pharmaceutical product is safe and efficacious for its intended use, and to determine warnings, precautions and adverse reactions that are associated with such pharmaceutical product in the dosage range to be prescribed, which trial is intended to support Approval of a Product, as described in 21 C.F.R. 312.21(c) for the United States, or a similar clinical study prescribed by the Regulatory Authorities in a foreign country.

  • Annual Work Plan means any of the Annual Work Plans.

  • Phase 1 Clinical Trial means a Clinical Trial of a Product on sufficient numbers of normal volunteers and/or patients that is designed to establish that such Product is safe for its intended use and to support its continued testing in Phase 2 Clinical Trials. For purposes of this Agreement, ‘initiation’ of a Phase 1 Clinical Trial for a Product means the first dosing of such Product in a human subject in a Phase 1 Clinical Trial.

  • Phase 3 Study means a clinical study of an investigational product in patients that incorporates accepted endpoints for confirmation of statistical significance of efficacy and safety with the aim to obtain Regulatory Approval in any country as described in 21 C.F.R. 312.21(c), or a comparable Clinical Study prescribed by the relevant Regulatory Authority in a country other than the United States. The investigational product can be administered to patients as a single agent or in combination with other investigational or marketed agents [***]

  • Work Plan means a plan that describes each individual activity to be conducted to complete eligible activities and the associated costs of each individual activity.

  • Vesting Commencement Date means the Grant Date or such other date selected by the Committee as the date from which an Award begins to vest.

  • Phase III means Phase I (or Phase I/II), Phase II (or Phase II/III) and Phase III clinical trials, respectively, in each case as prescribed by applicable FDA IND Regulations, or any corresponding foreign statutes, rules or regulations.

  • Phase II means the second part of the tuition incentive assistance program which provides assistance in the third and fourth year of 4-year degree programs.

  • Phase III Study means a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. § 312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  • Phase II Clinical Trial means a controlled human clinical study that would satisfy the requirements of 21 CFR 312.21(b), conducted to study the effectiveness and establish the dose range of a Product for a particular Indication in patients with the disease or condition under study, including a Phase IIA Clinical Study or Phase IIB Clinical Study.

  • Phase I Clinical Trial means a study in humans which provides for the first introduction into humans of a product, conducted in normal volunteers or patients to generate information on product safety, tolerability, pharmacological activity or pharmacokinetics, or otherwise consistent with the requirements of U.S. 21 C.F.R. §312.21(a) or its foreign equivalents.

  • Phase 4 Clinical Trial means a Clinical Study in any country which is conducted after Regulatory Approval of a product has been obtained from an appropriate Regulatory Authority, consisting of trials conducted voluntarily for enhancing marketing or scientific knowledge of an approved indication and trials conducted due to request or requirement of a Regulatory Authority.

  • Development Phase means the period before a vehicle type is type approved.

  • Phase II Clinical Study means a human clinical study of a product initiated to determine the safety and efficacy in the target patient population, as described 21 C.F.R. 312.21(b).

  • Phase 3 Clinical Trial means a pivotal clinical trial in humans performed to gain evidence with statistical significance of the efficacy of a product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an NDA and to provide an adequate basis for physician labeling, as described in 21 C.F.R. § 312.21(c) or the corresponding regulation in jurisdictions other than the United States.

  • Project area plan means a written plan that, after the plan's effective date, guides and controls the development within a project area.